NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that independent analyst Robert LeBoyer of Noble Capital Markets has initiated research coverage of the company with an “Outperform” rating and a $6.00 price target. The report reviews the company's lead programs, including its broad-spectrum antiviral candidate NV-387, along with longer-term development initiatives. NanoViricides noted that while it provided publicly available information and answered technical questions, the analyst independently developed all estimates, financial models and projections.
Separately, the company announced that President and Executive Chairman Anil R. Diwan participated in a “Fireside Chat” published by StockInvestor Daily's IPO-Edge program, where he discussed NanoViricides' antiviral technology platform, the potential of NV-387 against multiple viral diseases and variants, the company's regulatory progress, including FDA Orphan Drug Designation and its Rare Pediatric Disease Designation filing for measles, as well as the resurgence of infectious diseases such as measles, mpox and Ebola.
The initiation of coverage by Noble Capital Markets underscores the growing interest in NanoViricides' novel approach to antiviral therapy. The company's lead drug candidate, NV-387, is a broad-spectrum antiviral that the company plans to develop as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections, and even Measles. This wide-ranging potential could address significant unmet medical needs, particularly as infectious diseases continue to resurge globally.
NanoViricides' platform technology is based on special purpose nanomaterials designed to attack viruses. The company's business model involves licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses. In addition to NV-387, the company is developing drugs against a number of viral diseases, including oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
The company also noted that it has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of various human viral diseases.
Investors and industry observers will be watching closely as NanoViricides advances NV-387 into Phase II human clinical trials. The company cannot project an exact date for filing an IND for any of its drugs due to dependence on external collaborators and consultants. As with any drug development efforts, there can be no assurance that any of the company's pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development.
For more information, visit the company's newsroom at https://ibn.fm/NNVC.
